Picture of Opthea logo

OPT Opthea Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousSmall CapMomentum Trap

Momentum

Relative Strength (%)
1m+10.82%
3m+42.19%
6m+84.26%
1yr-31.72%
Volume Change (%)
10d/3m-22.29%
Price vs... (%)
52w High-14.48%
50d MA+22.01%
200d MA+42.34%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-123.38%
Return on Equity-3383.08%
Operating Margin-141098.16%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Jun 202430th Jun 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Opthea EPS forecast chart

Profile Summary

Opthea Limited is an Australia-based biotechnology company. The Company is engaged in the development and commercialization of therapies primarily for eye disease. The Company’s lead asset, OPT-302, is a novel biologic inhibitor of VEGF-C and VEGF-D, for use in combination with VEGF-A inhibitors for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The Company’s principal activities include the progression of the Company’s Phase III registration trials of OPT-302 for wet AMD. It also manufactures OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. The Company’s development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).

Directors

Last Annual
June 30th, 2023
Last Interim
December 31st, 2023
Incorporated
October 17th, 1984
Public Since
April 9th, 1985
No. of Shareholders
7,448
No. of Employees
5
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Select Market
Shares in Issue
662,808,634
Blurred out image of a map
Address
Suite 0403, MELBOURNE, 3141
Web
https://opthea.com/
Phone
+61 398260399
Auditors
Deloitte Touche Tohmatsu

OPT Share Price Performance

Similar to OPT

Picture of 2Seventy Bio logo

2Seventy Bio

us flag iconNASDAQ Global Select Market

Picture of 4D Molecular Therapeutics logo

4D Molecular Therapeutics

us flag iconNASDAQ Global Select Market

Picture of AbCellera Biologics logo

AbCellera Biologics

us flag iconNASDAQ Global Select Market

Picture of AbSci logo

AbSci

us flag iconNASDAQ Global Select Market

Picture of Acadia Pharmaceuticals logo

Acadia Pharmaceuticals

us flag iconNASDAQ Global Select Market

FAQ